Efficacy of Ibrexafungerp (SCY-078) against Candida auris in an <i>In Vivo</i> Guinea Pig Cutaneous Infection Model
Mahmoud A. Ghannoum, N. Isham, D. Angulo, Katyna Borroto–Esoda, Stephen Barat, L. Long
Abstract
Candida auris has been shown to have a high risk of skin colonization in hospitalized patients, possibly contributing to nosocomial spread. In a guinea pig skin model, animals were evaluated for clinical appearance, tissue fungal burden, histology, and pharmacokinetics. Oral dosing with 10 mg/kg ibrexafungerp (IBX) reduced the severity of lesions and significantly reduced the C. auris fungal burden in infected animals compared with untreated controls.
Topics & Concepts
Candida aurisGuinea pigPharmacokineticsDosingIn vivoMedicineSkin infectionColonizationBiologyInternal medicineDermatologyMicrobiologyAntifungalStaphylococcus aureusBacteriaBiotechnologyGeneticsAntifungal resistance and susceptibilityFungal Infections and StudiesNail Diseases and Treatments